Der Gynäkologe

, Volume 45, Issue 9, pp 684–689 | Cite as

Zukünftige Entwicklung der Geburtsmedizin

Blick in die Klinik
Leitthema

Zusammenfassung

Die zentralen Probleme der Geburtsmedizin haben sich trotz der erweiterten medizinischen Erkenntnisse und der technischen Innovationen seit vielen Jahren nicht verändert. Nach wie vor stellen Frühgeburtlichkeit, Präeklampsie, fetale Wachstumsretardierung und fetale Fehlbildungen die klinisch tätigen Perinatologen vor große Herausforderungen. Da bei Erstkontakt mit der Klinik aufgrund der entsprechenden Schwangerschaftskomplikationen zeitlich meist keine grundlegende Therapie mehr möglich ist, fokussiert die heutige Schwangeren- und Geburtsmedizin auf eine individualisierte Präventionsstrategie. Diese richtet die Betreuung der Patientin an dem Risikoprofil der Schwangerschaft aus, das möglichst frühzeitig in der Schwangerschaft ermittelt wird. Durch neue Behandlungsansätze kann eine aktive Reduktion des individuellen Risikos erreicht werden.

Schlüsselworte

Pränataldiagnostik Frühgeburt Fehlbildungen Präeklampsie Trisomie 

Future developments in obstetrics

View of clinical aspects

Abstract

The core problems in prenatal medicine have not changed in recent years despite progress in medical knowledge and technical innovations. The challenges for obstetricians are still preterm birth, preeclampsia, intrauterine growth restriction and fetal anomalies. At the time when treatment in hospital due to these problems becomes necessary, a fundamental treatment is in most cases no longer possible; therefore, modern prenatal medicine focuses on an individualized preventive medicine strategy. For all of these problems it is possible to compute a patient-specific risk at the beginning of pregnancy that can be used to identify high risk patients who need intensive care treatment. New treatment strategies can help to lower the risk in this high risk group.

Keywords

Prenatal diagnosis Premature birth Anomalies Preeclampsia Trisomy 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Nicolaides KH (2011) Turning the pyramid of prenatal care. Fetal Diagn Ther 29:183–196PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization (2005) The World Health Report 2005: make every mother and child count (World Health Reports). World Health Organization, Geneva, S 252Google Scholar
  3. 3.
    Yu CK, Khouri O, Onwudiwe N et al (2008) Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 31:310–313PubMedCrossRefGoogle Scholar
  4. 4.
    MacKay AP, Berg CJ, Atrash HK (2001) Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 97:533–538PubMedCrossRefGoogle Scholar
  5. 5.
    Meads CA, Cnossen JS, Meher S et al (2008) Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 12:iii–iv, 1–270Google Scholar
  6. 6.
    Papageorghiou AT, Yu CK, Bindra R et al (2001) Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 18:441–449PubMedCrossRefGoogle Scholar
  7. 7.
    Onwudiwe N, Yu CK, Poon LCY et al (2008) Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol 32:877–883PubMedCrossRefGoogle Scholar
  8. 8.
    Rumbold AR, Crowther CA, Haslam RR et al (2006) Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 354:1796–1806PubMedCrossRefGoogle Scholar
  9. 9.
    Poston L, Briley AL, Seed PT et a (2006) Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367:1145–1154PubMedCrossRefGoogle Scholar
  10. 10.
    De-Regil LM, Palacios C, Ansary A et al (2012) Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev 2:CD008873PubMedGoogle Scholar
  11. 11.
    Hofmeyr GJ, Atallah AN, Duley L (2006) Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev:CD001059Google Scholar
  12. 12.
    Bujold E, Roberge S, Lacasse Y et al (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116:402–414PubMedCrossRefGoogle Scholar
  13. 13.
    Cuckle HS (2011) Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 32(Suppl):42–48CrossRefGoogle Scholar
  14. 14.
    Akolekar R, Syngelaki A, Sarquis R et al (2011) Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 31:66–74PubMedCrossRefGoogle Scholar
  15. 15.
    Kagan KO, Wright D, Valencia C et al (2008) Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free-hCG and pregnancy-associated plasma protein-A. Hum Reprod 23:1968–1975PubMedCrossRefGoogle Scholar
  16. 16.
    Stumm M, Entezami M, Trunk N et al (2012) Noninvasive prenatal detection of chromosomal aneuploidies using different next generation sequencing strategies and algorithms. Prenat Diagn 32:569–577PubMedCrossRefGoogle Scholar
  17. 17.
    Syngelaki A, Chelemen T, Dagklis T et al (2011) Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 31:90–102PubMedCrossRefGoogle Scholar
  18. 18.
    Hyett J, Perdu M, Sharland G et al (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study. BMJ 318:81–85PubMedCrossRefGoogle Scholar
  19. 19.
    Pereira S, Ganapathy R, Syngelaki A et al (2011) Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol 117:1384–1391PubMedCrossRefGoogle Scholar
  20. 20.
    Chaoui R, Nicolaides KH (2010) From nuchal translucency to intracranial translucency: towards the early detection of spina bifida. Ultrasound Obstet Gynecol 35:133–138PubMedCrossRefGoogle Scholar
  21. 21.
    Bartlett LA, Berg CJ, Shulman HB et al (2004) Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 103:729–737PubMedCrossRefGoogle Scholar
  22. 22.
    Honest H, Forbes CA, Durée KH et al (2009) Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 13:1–627PubMedGoogle Scholar
  23. 23.
    Celik E, To M, Gajewska K et al (2008) Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment. Ultrasound Obstet Gynecol 31:549–554PubMedCrossRefGoogle Scholar
  24. 24.
    Vergnes J-N, Sixou M (2007) Preterm low birth weight and maternal periodontal status: a meta-analysis. Am J Obstet Gynecol 196:135.e1–e7PubMedCrossRefGoogle Scholar
  25. 25.
    Greco E, Gupta R, Syngelaki A et al (2012) First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther 31:154–161PubMedCrossRefGoogle Scholar
  26. 26.
    Greco E, Lange A, Ushakov F et al (2010) Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks. Prenat Diagn 31:84–89CrossRefGoogle Scholar
  27. 27.
    Czeizel AE, Dudás I, Métneki J (1994) Pregnancy outcomes in a randomised controlled trial of periconceptional multivitamin supplementation. Final report. Arch Gynecol Obstet 255:131–139PubMedCrossRefGoogle Scholar
  28. 28.
    Saling E, Schreiber M (2005) Laktobazillen-Schutzsystem bei Schwangeren – effiziente Vermeidung von Frühgeburten durch Früherkennung von Störungen. Z Geburtshilfe Neonatol 209:128–134PubMedCrossRefGoogle Scholar
  29. 29.
    Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group (2001) Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 357:989–994PubMedCrossRefGoogle Scholar
  30. 30.
    Lumley J, Chamberlain C, Dowswell T et al (2009) Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev:CD001055Google Scholar
  31. 31.
    Fonseca EB, Celik E, Parra M et al (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462–469PubMedCrossRefGoogle Scholar
  32. 32.
    Hassan SS, Romero R, Vidyadhari D et al (2011) Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 38:18–31PubMedCrossRefGoogle Scholar
  33. 33.
    Goya M, Pratcorona L, Merced C et al (2012) Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet 379:1800–1806PubMedCrossRefGoogle Scholar
  34. 34.
    Berghella V, Rafael TJ, Szychowski JM et al (2011) Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 117:663–671PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • K.O. Kagan
    • 1
  • M. Hoopmann
    • 1
  • H. Abele
    • 1
  • D. Wallwiener
    • 1
  1. 1.Perinatalzentrum Universitätsklinikum TübingenUniversitäts-FrauenklinikTübingenDeutschland

Personalised recommendations